S. Guran et al., P53, p15(INK4B), p16(INK4A) and p57(KIP2) mutations during the progressionof chronic myeloid leukemia, HAEMATOLOGI, 29(3), 1998, pp. 181-193
The occurrence of acute transformation during the treatment of chronic myel
oid leukemia (CML) is still a poorly understood mechanism. In this disease
p53, p16(INK4A), p15(INK4B), p57(KIP2) mutations and p15(INK4B)/p16(INK4A),
homo/hemizygous deletions were analyzed in the initial diagnosis phase and
during the treatment phase of twelve CML cases, in order to establish whet
her there was a consistent molecular genetic alteration in its progression.
During the treatment period, four of twelve cases had blastic crisis. All
the mutations observed in p53, p16(INK4A) and p15(INK4B) cumulated in three
out of four CML cases who had blastic crises. In one case, p53 codon 282 m
utation (CGG-->TGG; arg-->trp) were observed in initial diagnosis. Seven mo
nths later, G-->C transition in the 3' side of p15 cDNA (778. nucleotide) w
as observed in the accelerated phase with the same p53 codon 282 mutation.
Thirteen months later, this patient died as a result of blastic crisis. The
patient in blastic crises in the initial diagnosis phase had a mis-sense p
oint mutation in p16 codon 69 (ACT --> AGT; thr --> ser) and a polymorphism
in codon 68 (GCC --> GCG). Six months later, this patient also died. In on
e case, p53 codon 237 mutation (ATG --> ATA; met --> ile) were observed in
the initial diagnosis phase. Then months later, the patient died as a resul
t of blastic crises. No p15(INK4B)/p16(INK4A) homo/hemizygous deletion and
p57KIP2 gene mutation which was described in the same pathway were observed
in CML progression. These results indicate that p15(INK4B) and p16(INK4A)
gene alterations may have an affect on the progression of CML-like p53 muta
tion. A correlation was found with the progression of CML and p53, p16(INK4
B) and p16(INK4A) somatic mutations. Finding p15(INK4B) and p16(INK4A) gene
alteration as well as p53 mutations may be a prognostic marker in patients
with CML.